335 related articles for article (PubMed ID: 36831044)
1. Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC.
Goh KY; Cheng TY; Tham SC; Lim DW
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831044
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
4. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
5. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC.
Oitabén A; Fonseca P; Villanueva MJ; García-Benito C; López-López A; Garrido-Fernández A; González-Ojea C; Juaneda-Magdalena L; Lázaro ME; Martínez-Fernández M
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681606
[TBL] [Abstract][Full Text] [Related]
6. Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead.
Hita-Millan J; Carracedo A; Fernandez-Rozadilla C
J Pers Med; 2021 Sep; 11(10):. PubMed ID: 34683113
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
8. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors.
Brocco D; Lanuti P; Pieragostino D; Cufaro MC; Simeone P; Bologna G; Di Marino P; De Tursi M; Grassadonia A; Irtelli L; De Lellis L; Veschi S; Florio R; Federici L; Marchisio M; Miscia S; Cama A; Tinari N; Del Boccio P
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546102
[TBL] [Abstract][Full Text] [Related]
10. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients.
Gkountakos A; Delfino P; Lawlor RT; Scarpa A; Corbo V; Bria E
Ther Adv Med Oncol; 2021; 13():17588359211006947. PubMed ID: 34104224
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.
Tang S; Qin C; Hu H; Liu T; He Y; Guo H; Yan H; Zhang J; Tang S; Zhou H
Cells; 2022 Jan; 11(3):. PubMed ID: 35159131
[TBL] [Abstract][Full Text] [Related]
13. Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Indini A; Rijavec E; Grossi F
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918661
[TBL] [Abstract][Full Text] [Related]
14. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
Bhalla S; Doroshow DB; Hirsch FR
Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
17. Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer.
Duchemann B; Remon J; Naigeon M; Cassard L; Jouniaux JM; Boselli L; Grivel J; Auclin E; Desnoyer A; Besse B; Chaput N
Transl Lung Cancer Res; 2021 Jun; 10(6):2937-2954. PubMed ID: 34295689
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Brozos-Vázquez EM; Díaz-Peña R; García-González J; León-Mateos L; Mondelo-Macía P; Peña-Chilet M; López-López R
Cancer Immunol Immunother; 2021 May; 70(5):1177-1188. PubMed ID: 33113004
[TBL] [Abstract][Full Text] [Related]
19. [Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in
Non-small Cell Lung Cancer].
Wang P; Tang C; Liang J
Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):503-512. PubMed ID: 34187157
[TBL] [Abstract][Full Text] [Related]
20. Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives.
Lu C; Zhang YC; Chen ZH; Zhou Q; Wu YL
Front Oncol; 2022; 12():836891. PubMed ID: 35359372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
